21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
19:54 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Daiichi reports Phase I responses for U3-1402 in HER3-positive breast cancer

Daiichi Sankyo Co. Ltd. (Tokyo:4568) said U3-1402 led to a confirmed overall response rate (ORR) of 47% and a disease control rate of 94% in 32 evaluable patients with HER3-positive metastatic breast cancer who are...
14:28 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Merrimack discontinues pancreatic cancer candidate after Phase II miss

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) reported that first-line treatment with istiratumab (MM-141) missed the primary and secondary endpoints in the Phase II CARRIE trial to treat metastatic pancreatic cancer. The company said it will discontinue the...
19:31 , Jun 25, 2018 |  BC Extra  |  Clinical News

Merrimack falls on Phase II pancreatic cancer failure

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) lost $4.01 (44%) to $5.14 on Monday after reporting that first-line treatment with istiratumab (MM-141) missed the primary and secondary endpoints in the Phase II CARRIE trial to treat metastatic pancreatic...
22:54 , Jun 20, 2018 |  BC Extra  |  Preclinical News

Broad ErbB inhibition arrests KRAS mutant cancer

Multi-ErbB inhibitors may provide a treatment option for K-Ras (KRAS)-driven lung cancer where ErbB family member EGFR1-specific therapies have failed, according to two studies published in Science Translational Medicine on Wednesday. The findings suggest a...
00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...